Ohr Pharmaceutical Inc. (OHRP) Jumps 6.63% on January 25

Equities Staff |

Ohr Pharmaceutical Inc. (OHRP) was among the biggest gainers on the Russell 2000 for Monday January 25 as the stock popped 6.63% to $3.86, representing a gain of $0.24 per share. Some 281,711 shares traded hands on 978 trades, compared with an average daily volume of 452,848 shares out of a total float of 30.33 million. The stock opened at $3.59 and traded with an intraday range of $4.03 to $3.59.

After today's gains, Ohr Pharmaceutical Inc. reached a market cap of $117.08 million. Ohr Pharmaceutical Inc. has had a trading range between $12.31 and $2.02 over the last year, and it had a 50-day SMA of $4.46 and a 200-day SMA of $3.25.

Ohr Pharmaceutical Inc is a pharmaceutical company engaged in the development of the Company's previously acquired compounds.

Ohr Pharmaceutical Inc. is based out of New York, NY and has some 16 employees. Its CEO is Jason Slakter.

For a complete fundamental analysis analysis of Ohr Pharmaceutical Inc., check out Equities.com’s Stock Valuation Analysis report for OHRP. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

GoCoin

Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

Lyft

Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…